Tetraphase Pharmaceuticals (NASDAQ:TTPH) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40), Morningstar.com reports. Tetraphase Pharmaceuticals had a negative return on equity of 65.89% and a negative net margin of 432.40%.

TTPH opened at $1.30 on Friday. Tetraphase Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $4.49. The company has a market capitalization of $66.50 million, a P/E ratio of -0.49 and a beta of 2.99.

Several analysts recently issued reports on TTPH shares. Robert W. Baird reissued a “buy” rating and issued a $3.00 price target on shares of Tetraphase Pharmaceuticals in a report on Monday, January 7th. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 23rd. B. Riley started coverage on Tetraphase Pharmaceuticals in a report on Friday, January 4th. They issued a “buy” rating and a $3.00 price target on the stock. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $4.00 price target (down previously from $6.00) on shares of Tetraphase Pharmaceuticals in a report on Friday. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $4.54.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Paloma Partners Management Co acquired a new stake in Tetraphase Pharmaceuticals in the 4th quarter valued at approximately $33,000. Gamco Investors INC. ET AL increased its position in shares of Tetraphase Pharmaceuticals by 42.9% during the 4th quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 15,000 shares during the period. SG Americas Securities LLC acquired a new position in shares of Tetraphase Pharmaceuticals during the 4th quarter valued at $69,000. Rhumbline Advisers increased its position in shares of Tetraphase Pharmaceuticals by 40.6% during the 4th quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 21,089 shares during the period. Finally, Alambic Investment Management L.P. increased its position in shares of Tetraphase Pharmaceuticals by 31.0% during the 4th quarter. Alambic Investment Management L.P. now owns 114,874 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 27,170 shares during the period. Hedge funds and other institutional investors own 44.12% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2019/03/15/tetraphase-pharmaceuticals-ttph-posts-quarterly-earnings-results-meets-expectations.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Further Reading: What is a blue-chip stock?

Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.